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Abstract
Few other diseases exert such a huge toll of suffering as influenza. We report here that intranasal (i.n.) administration of E1/
E3-defective (DE1E3) adenovirus serotype 5 (Ad5) particles rapidly induced an anti-influenza state as a means of
prophylactic therapy which persisted for several weeks in mice. By encoding an influenza virus (IFV) hemagglutinin (HA)
HA1 domain, an Ad5-HA1 vector conferred rapid protection as a prophylactic drug followed by elicitation of sustained
protective immunity as a vaccine for inducing seamless protection against influenza as a drug-vaccine duo (DVD) in a single
package. Since Ad5 particles induce a complex web of host responses, which could arrest influenza by activating a specific
arm of innate immunity to impede IFV growth in the airway, it is conceivable that this multi-pronged influenza DVD may
escape the fate of drug resistance that impairs the current influenza drugs.
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Introduction
Influenza is a resurging and emerging disease with virtually no
possibility of eradicating the causal virus which triggers seasonal as
well as pandemic influenza. As a zoonotic disease with the
potential to sicken both animals and humans [1], a designer IFV
can be rapidly generated by reverse genetics [2] and disseminated
by terrorists to ravage agriculture, public health, and economy
within a targeted region. Even though this highly contagious and
potentially fatal disease has been partially controlled by vaccina-
tion, the licensed influenza vaccine is difficult to mass-produce [1]
and unable to confer timely as well as broad protection against
heterosubtypic IFV strains [3]. Another line of defense against
influenza is the use of influenza drugs [e.g., oseltamivir (Tamiflu);
zanamivir (Relenza)]; however, this option is limited by the
emergence of drug-resistant IFV due to selection under mutational
pressure [4,5].
To develop a rapid-response anti-influenza agent, we serendip-
itously demonstrated that an Ad5-vectored nasal influenza vaccine
could confer rapid protection against influenza in a drug-like
manner. A replication-competent adenovirus (RCA)-free Ad5
vector encoding pathogen antigens thus potentially can confer
seamless protection against mucosal pathogens as a DVD in a
wide variety of clinical settings. RCA-free Ad5 vectors can be
rapidly mass-produced in serum-free PER.C6 suspension cells;
painlessly mass-administered by nasal spray [1]; followed by
elicitation of innate as well as adaptive immune responses in the
face of pre-existing Ad5 immunity. In the case of an influenza
DVD, the chance to generate drug-resistant IFV is minimal since
Ad5 particles conceivably induce an anti-influenza state without
directly attacking the IFV. In contrast to a live attenuated IFV
vaccine (LAIV), an Ad5-vectored DVD is non-replicating and
does not reassort with wild IFV. It is expected that nasal spray of
an Ad5-vectored influenza DVD can confer broad protection
against heterosubtypic IFV strains for several weeks as a prophy-
lactic drug; followed by elicitation of strain-specific protective
immunity as a vaccine for months or even years before the drug-
induced protection declines away. This novel regimen may add a
rapid-response tool to the public health arsenal against influenza
and other diseases if the DVD’s protective effects should be
reproduced in human subjects.
Results
The DE1E3 Ad5 particle as an anti-influenza agent
The transgene-free DE1E3 Ad5 empty (AdE) particle and its
counterpart AdNC.H1.1 encoding the A/New Caledonia/20/99
H1N1 IFV (NC20) HA1 domain were generated in PER.C6 cells
as described [1]. As shown in Fig. 1, i.n. instillation of 1.7610
8
infectious units (ifu) of AdE 2 days (day -2) prior to challenge
protected 100% (10/10) of mice against a lethal dose of live A/
Puerto Rico/8/34 H1N1 IFV (PR8); only 20% (2/10) of the
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22605animals were protected when AdE’s dose was reduced 100-fold to
1.7610
6 ifu; and there was no protection when 1.7610
8 ifu of
AdE were administered into mice by i.n. instillation 1 day post-
PR8 challenge or by i.m. injection on day -2. Insertion of the
NC20 HA1 domain into the AdE genome mildly interfered with
DE1E3 Ad5’s capacity to induce an anti-influenza state as only
70% (7/10) of animals were protected when 1.7610
8 ifu of
AdNC.H1.1 were i.n. administered into mice on day -2. Similar to
AdE, neither i.n. instillation of 1.7610
6 ifu nor i.m. injection of
1.7610
8 ifu of AdNC.H1.1 conferred any protection against PR8
when administered on day -2 (Fig. 1). The protection afforded by
i.n. administration of AdE (P,0.0001) or AdNC.H1.1 (P=0.0077)
at a dose of 1.7610
8 ifu on day -2 reached statistical significance
when compared to that of the untreated control group (by Log-
rank tests).
Intranasal administration of AdE on day -47 (47 days prior to
PR8 challenge) protected 70% of animals (7/10) showing that the
AdE-induced anti-influenza state could persist for several weeks
(Fig. 2). Intranasal instillation of AdNC.H1.1 on day -47 protected
100% (10/10) of mice (Fig. 2) presumably due to NC20 HA1-
induced adaptive immunity which cross-reacted with PR8 even
though no serum hemagglutination-inhibition (HI) antibodies
to PR8 were detectable (Table 1). Unlike immunization with
AdNC.H1.1 on day -47 which elicited high HI antibody titers to
NC20 and undetectable titers to PR8, challenge with PR8 induced
high HI antibody titers to PR8 and low titers to NC20 in sur-
vivors, and administration of either AdE or AdNC.H1.1 on day -2
induced HI titers to neither NC20 nor PR8 (Table 1). The
protection afforded by i.n. administration of AdNC.H1.1 on day -
47 (P,0.0001), AdE on day -47 (P=0.0032), AdE double-dose
regimen (day -47 followed by a booster application on day -2)
(P,0.0001), AdE on day -1 (P,0.0001) or -2 (P=0.0005) at a dose
of 1.2610
8 ifu all reached statistical significance when compared
to that of the untreated control group.
Although several regimens protected mice against influenza-
mediated mortality, the AdE double-dose regimen tended to
confer more solid protection than its single-dose (day -47 or -2)
counterpart as shown by less body weight loss after PR8 challenge
even though the difference did not reach statistical significance
(Fig. 3). To induce an anti-influenza state, it is essential to delete
E1 and/or E3 since the E1
+/E3
+ wild-type Ad5 was unable to
arrest influenza after i.n. administration into mice under identical
conditions (Fig. 2).
Ad5-induced protection of the lung against influenza
As shown by lung histopathology after PR8 challenge, i.n.
administration of AdE or AdNC.H1.1 on day -2 protected mice
against influenza by preventing the development of severe lung
injuries. Intranasal instillation of PR8 without Ad5 protection
induced massive pulmonary inflammation 19 days post-challenge
Figure 1. Prophylactic therapy against lethal challenge by PR8 in mice. Prophylactic therapy was performed by i.n. administration of Ad5
particles shortly before PR8 challenge. AdE/in/-2 and AdE*/in/-2, i.n. administration of AdE on day -2; AdE/in/+1, i.n. administration of AdE 1 day post-
PR8 challenge; AdE/im/-2, i.m. injection of AdE on day -2; AdNC/in/-2 and AdNC*/in/-2, i.n. administration of AdNC.H1.1 on day -2; AdNC/im/-2, i.m.
injection of AdNC.H1.1 on day -2; untreated control, Balb/c mice without treatment prior to PR8 challenge; all groups were inoculated with AdE or
AdNC.H1.1 at a dose of 1.7610
8 ifu except AdE*/in/-2 and AdNC*/in/-2 groups that received a dose of 1.7610
6 ifu; all groups were challenged by i.n.
instillation of 4xLD50 of PR8 on day 0; body weights were recorded daily for 18 days post-challenge with 30% body weight loss taken as the disease
endpoint; numbers in parentheses represent the number of animals in each group.
doi:10.1371/journal.pone.0022605.g001
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Intranasal administration of AdE (Fig. 4C) or AdNC.H1.1
(Fig. 4D) on day -2 greatly reduced the level of acute lung injury.
When the lung sections were examined microscopically under
higher magnification, it was visible that PR8 challenge without
Ad5 protection induced massive epithelialization of alveolar
tissues; multiple foci of monocytes; vascular congestion; early
fibrosis; hemorrhage; and perivascular cuffing (Fig. 4E). Prophylactic
therapy with AdE or AdNC.H1.1 prevented many of the PR8-
induced lung injuries from occurring although perivascular cuffing
was still common (Fig. 4G), and healthy blood vessels (Fig. 4H) as
well as healthy alveoli (Fig. 4G and H) could be found in the Ad5-
protected lungs. Ad5-mediated reduction of lung histopathology
wasinline with the arrestofPR8growthinthelungspost-challenge.
As shown in Fig. 5, the difference in PR8 titers between the lungs of
controlandAdE-exposedanimalsreached statisticalsignificance(by
Figure 2. Protection of mice by Ad5-mediated prophylactic therapy and vaccination against a higher dose of PR8 challenge. AdNC/
in/-47, i.n. administration of AdNC.H1.1 on day -47; AdE/in/-47, i.n. administration of AdE on day -47; AdE/in/-47-2, i.n. administration of AdE on day -
47 followed by a booster application of day -2; AdE/in/-1, i.n. administration of AdE on day -1; wtAd/in/-1, i.n. administration of E1
+/E3
+ wild-type Ad5
particles on day -1; all groups were inoculated with Ad5 particles at a dose of 1.2610
8 ifu followed by challenge with 10xLD50 of PR8 on day 0; body
weights were recorded daily for 14 days post-challenge; other symbols and protocols are the same as those described in Fig. 1 legend.
doi:10.1371/journal.pone.0022605.g002
Table 1. Serum HI antibody titers induced by AdNC.H1.1 immunization and PR8 challenge.
Immunization n
Day of serum
collection
Log2[anti-NC20
HI GMT] (±SD)
Seroconversion
to NC20 (%)
Log2[anti-PR8 HI
GMT] (±SD)
Seroconversion
to PR8 (%)
aAdNC/in/-2 + PR8 7 19 7.9 (60.5) 100 8.9 (60.5) 100
aAdE/in/-2 + PR8 10 19 5.3 (60.7) 100 7.5 (60.6) 100
bAdNC/in/-47 10 211 0 . 2 ( 61.7) 100 2.3 (60) 0
bAdNC/in/-2 10 21 2.3 (60) 0 2.3 (60) 0
bAdE/in/-2 10 21 2.3 (60) 0 2.3 (60) 0
bUntreated control 10 21 2.3 (60) 0 2.3 (60) 0
HI antibodies were measured against the respective IFV with titers expressed as GMT on a log2 scale; a log2 titer of 2.3 was arbitrarily assigned to samples with
undetectable titers; each serum sample was run in triplicate wells;
aanimals described in Fig. 1 with sera collected 19 days post-PR8 challenge;
banimals described in Fig. 2 with sera collected 1 day prior to PR8 challenge. Seroconversion was defined as $4-fold rise in HI titer above the preimmune baseline; n,
number of animals; GMT, geometric mean titer; SD, standard deviation.
doi:10.1371/journal.pone.0022605.t001
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days post-PR8 challenge.
Protection against a pandemic IFV strain
To demonstrate that DE1E3 Ad5 particles can protect mice
against not only PR8 but also a more clinically relevant IFV strain,
2.5610
8 ifu of AdE or AdNC.H1.1 were i.n. administered into
mice followed by challenging animals with a lethal dose of the
pandemic 2009 H1N1 swine flu isolate A/California/04/2009
(CA04). As shown in Fig. 6, 100% (10/10) of animals were
protected by i.n. instillation of AdE or AdNC.H1.1 on day -2 and
AdNC.H1.1 on day -22; 90% (9/10) were protected by i.n.
administration of AdE on day -22. The protection afforded against
CA04 in all these Ad5-exposed groups reached statistical sig-
nificance when compared to that of the placebo control group
(P,0.0001).
Discussion
The non-replicating DE1E3 Ad5 vector has been bioengineered
into a nasal influenza vaccine carrier with high potency and
excellent safety profile [1]. In addition to the elicitation of
protective immunity as a vaccine, we show here that this class of
vaccine can also confer prophylactic therapy against influenza
before adaptive immunity is elicited. It has been documented that
administration of DE1E3 Ad5 particles into mice rapidly induces
Figure 3. Health status of PR8-challenged animals as shown by body weight loss. Post-challenge body weights are presented as mean %
body weight by taking the body weight of individual mice on day 1 as 100%. Symbols and challenge protocols are the same as those described in
Figs. 1 and 2 legends. Although AdE/in/-47-2 and AdNC/in/-47 animals lost less weight than mice in other groups, the difference did not reach
statistical significance (by one-way ANOVA with Turkey’s multiple comparison post-tests; the untreated control group was excluded in statistical
analysis due to early termination of data points).
doi:10.1371/journal.pone.0022605.g003
Figure 4. Lung histopathology induced by PR8 infection. (A and E) Lung resected from an untreated control mouse (Fig. 1) 19 days post-PR8
challenge. (B and F) Lung resected from a normal Balb/c mouse as a control. (C and G) Lung resected from an AdE/in/-2 mouse (Fig. 1) 19 days post-
PR8 challenge; each section is a representative of three mice. (D and H) Lung resected from an AdNC/in/-2 mouse (Fig. 1) 19 days post-PR8 challenge;
each section is a representative of three mice. Lung sections were examined on a Zeiss Axioskop2 plus microscope using a 2X (A–D) or a 10X (E–H)
objective lens in conjunction with an Axiocam digital camera.
doi:10.1371/journal.pone.0022605.g004
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chemokines [6] including type I interferon (IFN-a and IFN-b) [7];
impairs lung dendritic cells [8]; activates natural killer cells [9];
induces production of the antiviral nitric oxide [10]; triggers multi-
faceted interactions between Ad5 and blood proteins, platelets,
macrophages, endothelial cells, and respective parenchymal cells
[6]. Inhibition of Ad5-associated inflammation by Ad5 E1A, E1B,
and E3 proteins [11] suggests that the E1
+/E3
+ Ad5’s incompe-
tence to induce an anti-influenza state (Fig. 2) may be attributed to
suppression of inflammation, although other mechanisms cannot
be excluded since DE1E3 Ad5 particles induce many immune
as well as non-immune responses and some reactions remain
undefined in animals [12]. It is conceivable that multiple reactions
induced by the DE1E3 Ad5 particles may integrate for establishing
an anti-influenza state in the airway, thus creating a multidimen-
sional defense barrier that can hardly be bypassed by an IFV. This
hypothesis is supported by the finding that the IFN-a/b receptor
provides protection against influenza in a dispensable manner
showing that animals have evolved overlapping mechanisms to
respond to influenza [13]. Furthermore, Balb/c mice challenged
in these studies carry a defective allele of the IFN-a/b-induced
influenza-resistance factor Mx1 [14] implying that the DE1E3
Ad5-induced production of type I IFN [7] may not play a major
role during the establishment of an anti-influenza state in this
mouse strain.
The finding that i.n. administration of AdE 1 day post-PR8
challenge was unable to arrest influenza (Fig. 1) suggests that the
IFV may induce a pro-influenza state that is not disrupted by the
DE1E3 Ad5 particle when the former enters the airway prior to
the latter, similar to the Ad5-induced anti-influenza state that
cannot be reversed by an IFV when AdE particles were i.n.
administered prior to PR8 or CA04 (Figs. 1, 2, 3, 4, 5, 6). To
further develop the DE1E3 Ad5-based prophylactic drug into a
post-exposure influenza drug, it is crucial to characterize the
antagonistic reactions induced by the two types of viruses in the
airway.
Pre-exposure to Ad5 has been associated with loss of Ad5’s
potency when this vector is i.m. injected [15]. However, emerging
evidence shows that an Ad5-vectored nasal vaccine can bypass
pre-existing Ad5 immunity in mice [15], macaques [16], and
humans [17] probably due to high-efficiency gene delivery into
cells in the superficial layer along the mucosal barrier in
conjunction with potent antigen presentation associated with this
immunocompetent interface tissue. The synergy between primary
and booster applications induced by the AdE double-dose regimen
(Figs. 2 and 3) shows that the rapid anti-influenza responses
induced by AdE were additive in the presence of pre-existing Ad5
immunity. These findings hold promise that this nasal influenza
DVD not only is able to induce rapid and sustained protection
against influenza in a single-dose regimen but also may be ad-
ministered repeatedly (e.g., when a different HA is required for its
vaccine component) without losing potency.
Although prophylactic influenza therapy can be performed by
i.n. administration of complex bacterial lysates [18] or bacterial
toxins [19], the bacterial component-induced anti-influenza state
was very transient with its protective effects declining within a few
days post-therapy [18,19]. The finding that AdE-induced
protective effects could persist for at least 3 weeks (Fig. 6) and
up to 47 days (Fig. 2) in a single-dose regimen suggests that the
underlying mechanisms between bacterial component- and Ad5-
induced anti-influenza states may differ. In addition, only the latter
would allow sufficient time for the DVD’s vaccine component to
elicit adaptive immunity before its drug effects decline away.
Moreover, the replicating wild-type Ad5 is a benign respiratory
virus and its non-replicating counterpart used in this study should
be even safer; notably, the safety profile of an Ad5-vectored nasal
influenza vaccine in human subjects has been shown [17]. As a
common respiratory virus, the human mucosal immune system is
familiar with Ad5 particles and must have evolved Ad5-specific
protective mechanisms. In contrast, administration of a digestive
tract-associated bacterial toxin into the respiratory tract as an
influenza drug [19] would surprise the immune system and this
unnatural regimen has been associated with the induction of Bell’s
palsy in human subjects [20].
The IFV is insidious in mutating into drug-resistant strains
when it is attacked by an influenza drug [e.g., the M2 ion channel
blocker (amantadine; rimantadine) or the neuraminidase inhibitor
(oseltamivir; zanamivir)] [5]. Unlike contemporary influenza
drugs, the Ad5-vectored DVD conceivably changes the habitat
in the respiratory tract without directly attacking the IFV; hence
the DVD confers no mutational pressure to induce drug resistance.
In contrast to the oseltamivir-induced suppression of mucosal
immunity with the risk to enhance vulnerability to subsequent
mucosal pathogen infections [21], the Ad5-vectored DVD en-
hances mucosal innate immunity against at least a subset of
mucosal pathogens. The DVD’s efficacy is further fortified by its
vaccine component that elicits sustained adaptive immunity before
its drug effects completely disappear (Figs. 1, 2, 3, 4, 5, 6). Since
the licensed LAIV (e.g., FluMistH in the U.S.) contains live IFV [1],
co-administration of LAIV with an influenza drug would be
counter-productive because the drug would disable the vaccine by
killing live IFV. The Ad5-vectored DVD not only is compatible
with a licensed influenza drug, but also it confers prophylactic
therapy as a drug by itself in addition to its vaccine capacity.
Emerging evidence shows that a number of nasal vaccines
induce a weaker systemic adaptive immune response than their
parenteral counterparts [22-26] even though nasal vaccines confer
Figure 5. PR8 titers in lungs post-challenge. AdE particles
(1.2610
8 ifu per 50 ml) were i.n. instilled into mice on day -2 followed
by challenging control and AdE-exposed mice with 4.6610
6 pfu of PR8
on day 0. Day 5, PR8 titers in lungs resected from control mice 5 days
post-PR8 challenge; AdE-Day 5, PR8 titers in lungs resected from AdE-
exposed mice 5 days post-PR8 challenge; Day 7, PR8 titers in lungs
resected from control mice 7 days post-PR8 challenge; AdE-Day 7, PR8
titers in lungs resected from AdE-exposed mice 7 days post-PR8
challenge; triangle and circle, log2(pfu of PR8)/g lung in individual mice;
bar, geometric mean of PR8 titers in lungs. No PR8 titers were detected
in lungs resected from control mice that were not challenged with PR8.
The difference between Day 7 and AdE-Day 7 reached statistical
significance (by one-way ANOVA with Turkey’s multiple comparison
post-tests).
doi:10.1371/journal.pone.0022605.g005
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eliciting a more potent mucosal adaptive immune response
[22,25]. We provide evidence that not only adaptive immunity
but also innate immunity could be induced with a focus on the
respiratory tract against mucosal pathogens when the DE1E3 Ad5
particle is administered i.n. but not i.m., as shown by % survival
afforded by i.n. and i.m. routes, respectively (Fig. 1). Whether the
Ad5-vectored nasal DVD can confer protection against influenza
induced by other routes (e.g., oral infection) remains to be seen.
The finding that i.n. administration of AdNC.H1.1 on day -47
induced more robust protection against PR8 challenge than its
counterpart inoculated on day -2 or AdE administered on day -47
(Figs. 1 and 2) suggests that animals in the AdNC/in/-47 group
may be protected by an NC20 HA1-mediated adaptive immune
response that cross-reacted with PR8 47 days post-immunization
in the absence of detectable serum HI antibody to PR8 (Table 1).
The data corroborate other reports that serum HI antibody titer is
an inadequate surrogate marker for predicting protective immu-
nity induced by a nasal influenza vaccine [24,26].
The findings that the Ad5-vectored DVD can confer prophy-
lactic therapy in conjunction with vaccination in a single package
provide a foundation for the development of a novel anti-influenza
agent that can be mass-produced in cultured cells, administered
painlessly by nasal spray, with the capacity to bypass pre-existing
Ad5 immunity and mobilize the innate as well as the adaptive
immune repertoires toward a rapid and sustained beneficial
response against influenza, without the potential to generate drug-
resistant IFV strains.
Materials and Methods
Adenovirus
To generate the AdE particle, homologous recombination
between the shuttle pAdHigh and the Ad5 backbone pAdEasy-1
plasmids was performed in Escherichia coli BJ5183 cells followed by
generation of the RCA-free AdE particle in PER.C6 cells
(provided by Crucell Holland BV; Leiden, The Netherlands)
as described [1]. AdE is thus a DE1E3 Ad5 with an expression
cassette in its E1 region [1] without encoding any transgene. To
generate the AdNC.H1.1 vector, the NC20 HA gene was
synthesized at GENEART (Regensburg, Germany) with codons
optimized to match the tRNA pool found in human cells in
Figure 6. Protection against lethal challenge by the pandemic CA04 in mice. AdE or AdNC.H1.1 particles (2.5610
8 ifu per 50 ml) were i.n.
instilled into mice at varying time points followed by CA04 challenge. AdE/in/-22, i.n. administration of AdE on day -22; AdNC/in/-22, i.n.
administration of AdNC.H1.1 on day -22; placebo control, i.n. administration of 50 ml saline on day -22; animals were challenged by i.n. instillation of
3xLD50 of the pandemic CA04 on day 0; other symbols and protocols are the same as those described in Fig. 1 legend.
doi:10.1371/journal.pone.0022605.g006
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site immediately upstream from the initiation ATG codon [27].
The NC20 HA1 fragment containing 347 amino acids was
amplified from the synthetic HA template by polymerase chain
reaction (PCR) using primers 59-CACAGGTACCGCCACCAT-
GAAGGCCAAGCTG-39 and 59-GAGTCTAGATTATCAGC-
CGAACAGGCCTCTGCTCTGG-39. The KpnI-XbaI fragment
containing the amplified HA1 fragment with a stop codon added
in-frame was inserted into the KpnI-XbaI site of pAdHigh in the
correct orientation under transcriptional control of the human
cytomegalovirus (CMV) early promoter. An RCA-free Ad5 vector
encoding the NC20 HA1 (AdNC.H1.1) was subsequently
generated in PER.C6 cells as described above. Both AdE and
AdNC.H1.1 were validated by DNA sequencing; mass-produced
in PER.C6 cells; purified by ultracentrifugation over a cesium
chloride gradient as described [27]; dialyzed into A195 buffer [28]
with titers (ifu per ml) determined in 293 cells [17] by the
Spearman-Karber method [29] after staining Ad5-infected mono-
layers with a horseradish peroxidase (HRP)-conjugated anti-Ad5
hexon antibody and the 3,39-diaminobenzidine tetrahydrochloride
(DAB) substrate (Clontech Laboratories, Inc.; Mountain View,
CA). The E1
+/E3
+ wild-type Ad5 (VR-1516) was obtained from
the American Type Culture Collection (ATCC; Manassas, VA).
Influenza virus
PR8 (VR-95) was obtained from the ATCC and grown in
Madin Darby Canine Kidney (MDCK) cells in the presence of
TPCK-trypsin as described [17] with titers determined by plaque
assay [30]. The mouse-adapted CA04 was generated by Natalia A.
Ilyushina and provided by Elena Govorkova at the St. Jude
Children’s Research Hospital (Memphis TN). The CA04 virus was
adapted to replication in the lungs of Balb/c mice by 9 sequen-
tial passages through mouse lungs. Virus was plaque purified in
MDCK cells and a virus stock was prepared by growth in 10-
day-old embryonated chicken eggs and then MDCK cells as
described [31] with titers expressed as cell culture infectious doses
(CCID50) as described [32]. NC20 was provided by the Center for
Disease Control (CDC; Atlanta, GA).
Challenge studies
Intranasal administration and i.m. injection of 50 ml of Ad5
particles into young (approximately 2 months old) female Balb/c
mice were performed as described [27]. Mice were challenged by
i.n. instillation of 50 ml of PR8 containing either 1.4610
6 plaque-
forming units (pfu) [equivalent to approximately 4xLD50 (50%
lethal dose)] or 3.5610
6 pfu (equivalent to approximately
10xLD50) at University of Alabama at Birmingham (UAB), as
well as 90 ml of CA04 containing 2610
5 CCID50 (equivalent to
approximately 3xLD50) at Utah State University (USU). All ex-
periments using mice were performed in accordance with the
approval of the Institutional Animal Care and Use Committees at
UAB and USU (UAB Approval ID, #7705; UAB Animal Welfare
Assurance Number, A3255-01; USU Approval ID, #552; USU
Animal Welfare Assurance Number, A3801-01). Animal facilities
at both UAB and USU have been AAALAC accredited.
PR8 titers in lungs post-challenge
AdE particles were i.n. administered into young female Balb/c
mice at a dose of 1.2610
8 ifu in a volume of 50 ml on day -2. Five
to seven days after i.n. instillation of 4.6610
6 pfu of PR8 on day 0,
control and AdE-exposed mouse lungs were immediately frozen
on dry ice after resection and stored at 280uC until analysis. After
thawing, a fraction of each lung was weighed and homogenized in
cold phosphate buffered saline (PBS) as a 10% (w/v) suspension.
Tissue debris was removed by centrifugation and the supernatant
was transferred to another sterile tube for virus titration. Plaque
assay of IFV was performed as described [30].
Hemagglutination-inhibition assay
Sera were tested for activity against PR8 or NC20 by standard
HI assay after pre-treatment of the sera with a receptor-destroying
enzyme as described [17]. Each serum sample was tested
beginning at a dilution of 1:10. All sera were tested in a blinded
fashion on code-labeled, matched pre- and post-immunization
samples. Animals were considered seronegative and assigned an
HI antibody titer of 5 (2.3 on a log2 scale) if their serum specimen
had an HI titer of ,10.
Lung histopathology assay
Mouse lungs were fixed by perfusing 10% buffered formalin
through the trachea. Paraffin-embedded tissues were cut into 5- mm-
thick slices followed by staining sections with hematoxylin and eosin.
Statistical analysis
All statistical analysis was performed using GraphPad Prism
version 5.04 (GraphPad Software, San Diego, CA). Log-rank tests
were performed for comparing Kaplan-Meier survival curves; and
one-way ANOVA with Turkey’s multiple comparison post-tests
were performed for comparing body weight loss as well as PR8
titers in lungs. Statistical significance was set at P,0.05.
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